Antibody development includes:
In vitro display technologies offer unique advantages over hybridoma technology, particularly for challenging targets like integral membrane proteins.
iMAb uses proprietary computer-designed synthetic repertoires of human mAbs optimized for diversity, expression, and affinity for in vitro screening.
iMAb is a biotech company with an integrated approach to develop human antibodies.
The company was spun out from Inserm and uses proprietary know-how and a highly diverse library containing billions of candidate antibodies.
(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, ... (many of them cross-reactive human/mouse)
iMAb - Servier collaboration
iMab and Servier join forces to discover therapeutic antibodies against autoimmune disease
iMAb - Iama collaboration
iMAb and Iama join forces to discover novel therapeutic human antibodies
June 24-25, 2019
Meet iMAb at the 7th Antibody Industrial Symposium 2019 (AIS2019). This year's topic is “Harnessing the immune system with therapeutic antibodies”
iMAb - ADC Therapeutics collaboration
April 9, 2019
iMAb and ADC Therapeutics join forces to discover novel therapeutic human antibodies
March 4-5, 2019
Meet iMAb at the Festival of Biologics, at the Americas Antibody Congress bringing together the pioneers doing the most innovative work within the industry and across the whole value chain.
November 5-7, 2018
Meet iMAb at the 24th annual BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry
October 29-31, 2018
Meet iMAb at the Festival of Biologics, a technology exhibition for the biologics community gathering 1200 antibody, biosimilar, immunotherapy and high potency API development professionals, as well as leading academics and innovative suppliers.
iMAb, Institut de Recherche en Cancérologie de Montpellier, Campus Val d'Aurelle, 34298 Montpellier cedex 5, France